Nilotinib: A Novel, Selective Tyrosine Kinase InhibitorBLAY, Jean-Yves; VON MEHREN, Margaret.Seminars in oncology. 2011, Vol 38, Num 2, issn 0093-7754, S3-S9, SUP1Article

NilotinibDEININGER, Michael W.Clinical cancer research. 2008, Vol 14, Num 13, pp 4027-4031, issn 1078-0432, 5 p.Article

Nilotinib. CommentariesROSTI, Gianantonio; LE COUTRE, Philipp.Drugs (Basel). 2008, Vol 68, Num 4, pp 460-461, issn 0012-6667, 2 p.Article

Nilotinib ameliorates lipopolysaccharide-induced acute lung injury in ratsEL-AGAMY, Dina S.Toxicology and applied pharmacology. 2011, Vol 253, Num 2, pp 153-160, issn 0041-008X, 8 p.Article

Intensified Inflammatory Reaction of Actinic Keratoses after Single Application of Topical 5-Fluorouracil in a Patient Treated with Nilotinib for Chronic Myeloid LeukemiaSCHMID-WENDTNER, Monika-Hildegard; WENDTNER, Clemens M.Dermatology (Basel). 2009, Vol 219, Num 4, pp 341-343, issn 1018-8665, 3 p.Article

Toxidermie à l'imatinib suivie d'une toxidermie au nilotinib = Successive cutaneous adverse reactions to nilotinib and imatinib in a single patientLAMCHAHAB, M; QACHOUH, M; HALI, F et al.Annales de dermatologie et de vénéréologie. 2012, Vol 139, Num 12, pp 828-831, issn 0151-9638, 4 p.Article

The skeletal effects of the tyrosine kinase inhibitor nilotinibO'SULLIVAN, Susannah; LIN, Jian-Ming; CORNISH, Jillian et al.Bone (New York, NY). 2011, Vol 49, Num 2, pp 281-289, issn 8756-3282, 9 p.Article

Nilotinib : effets indésirables cardiovasculairesLa Revue Prescrire. 2013, Vol 33, Num 359, issn 0247-7750, p. 667Article

Effects of famotidine or an antacid preparation on the pharmacokinetics of nilotinib in healthy volunteersYIN, Ophelia Q. P; BEDOUCHA, Véronique; MCCULLOCH, Tracey et al.Cancer chemotherapy and pharmacology. 2013, Vol 71, Num 1, pp 219-226, issn 0344-5704, 8 p.Article

Nilotinib-induced hypothyroidism in a patient with chronic myeloid leukemiaYOSHIZATO, Tetsuichi; NANNYA, Yasuhito; YOSHIKI, Yumiko et al.International journal of hematology. 2011, Vol 93, Num 3, pp 400-402, issn 0925-5710, 3 p.Article

Effects of Hepatic Impairment on the Pharmacokinetics of Nilotinib: An Open-Label, Single-Dose, Parallel-Group StudyYIN, Ophelia Q. P; GALLAGHER, Neil; TANAKA, Chiaki et al.Clinical therapeutics. 2009, Vol 31, Num THEM, pp 2459-2469, issn 0149-2918, 11 p., 2Article

Clinical cardiac safety profile of nilotinibKIM, Theo D; LE COUTRE, Philipp; SCHWARZ, Michaela et al.Haematologica (Roma). 2012, Vol 97, Num 6, pp 883-889, issn 0390-6078, 7 p.Article

Combined effects of novel heat shock protein 90 inhibitor NVP-AUY922 and nilotinib in a random mutagenesis screenTAUCHI, T; OKABE, S; ASHIHARA, E et al.Oncogene (Basingstoke). 2011, Vol 30, Num 24, pp 2789-2797, issn 0950-9232, 9 p.Article

In vitro testing of drug combinations employing nilotinib and alkylating agents with regard to pretransplant conditioning treatment of advanced-phase chronic myeloid leukemiaRADUJKOVIC, Aleksandar; LUFT, Thomas; DREGER, Peter et al.Cancer chemotherapy and pharmacology. 2014, Vol 74, Num 2, pp 427-432, issn 0344-5704, 6 p.Article

Inhibition of PDGF, TGF-β, and Abl signaling and reduction of liver fibrosis by the small molecule Bcr-Abl tyrosine kinase antagonist NilotinibYUQING LIU; ZHUO WANG; KWONG, Shu Qin et al.Journal of hepatology. 2011, Vol 55, Num 3, pp 612-625, issn 0168-8278, 14 p.Article

Nilotinib as frontline therapy for patients with newly diagnosed Ph+ chronic myeloid leukemia in chronic phase: results from the Japanese subgroup of ENESTndNAKAMAE, Hirohisa; SHIBAYAMA, Hirohiko; AMAGASAKI, Taro et al.International journal of hematology. 2011, Vol 93, Num 5, pp 624-632, issn 0925-5710, 9 p.Article

Clinical Experience to Date With Nilotinib in Gastrointestinal Stromal TumorsREICHARDT, Peter; MONTEMURRO, Michael.Seminars in oncology. 2011, Vol 38, Num 2, issn 0093-7754, S20-S27, SUP1Article

Nilotinib As Front-Line Treatment for Patients With Chronic Myeloid Leukemia in Early Chronic PhaseCORTES, Jorge E; JONES, Dan; KANTARJIAN, Hagop et al.Journal of clinical oncology. 2010, Vol 28, Num 3, pp 392-397, issn 0732-183X, 6 p.Article

Pharmacokinetics and Pharmacodynamics of Nilotinib in Gastrointestinal Stromal TumorsTRENT, Jonathan; MOLIMARD, Mathieu.Seminars in oncology. 2011, Vol 38, Num 2, issn 0093-7754, S28-S33, SUP1Article

Inhibition of c-Kit signaling is associated with reduced heat and cold pain sensitivity in humansCEKO, Marta; MILENKOVIC, Nevena; LE COUTRE, Philipp et al.Pain (Amsterdam). 2014, Vol 155, Num 7, pp 1222-1228, issn 0304-3959, 7 p.Article

Calcium carbonate does not affect nilotinib pharmacokinetics in healthy volunteersTAWBI, Hussein A; TRAN, An L; BEUMER, Jan H et al.Cancer chemotherapy and pharmacology. 2013, Vol 72, Num 5, pp 1143-1147, issn 0344-5704, 5 p.Article

Nilotinib exacerbates diabetes mellitus by decreasing secretion of endogenous insulinITO, Yoshikiyo; MIYAMOTO, Toshihiro; YONG CHONG et al.International journal of hematology. 2013, Vol 97, Num 1, pp 135-138, issn 0925-5710, 4 p.Article

Macromolecular Changes in Nilotinib Resistant K562 Cells; an In vitro Study by Fourier Transform Infrared Spectroscopy : Advances in Optical Imaging and Cancer ResearchCEYLAN, Cagatay; CAMGOZ, Aylin; BARAN, Yusuf et al.Technology in cancer research & treatment (Print). 2012, Vol 11, Num 4, pp 333-344, issn 1533-0346, 12 p.Article

Population pharmacokinetic and exposure-response analysis of nilotinib in patients with newly diagnosed Ph+ chronic myeloid leukemia in chronic phaseLARSON, Richard A; YIN, Ophelia Q. P; LE COUTRE, Philipp D et al.European journal of clinical pharmacology. 2012, Vol 68, Num 5, pp 723-733, issn 0031-6970, 11 p.Article

Clinical impact of dose reductions and interruptions of second- generation tyrosine kinase inhibitors in patients with chronic myeloid leukaemiaSANTOS, Fabio P. S; KANTARJIAN, Hagop; FAVA, Carmen et al.British journal of haematology. 2010, Vol 150, Num 3, pp 303-312, issn 0007-1048, 10 p.Article